Gabapentin Capsule
Product Images NDC 70518-2911

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2911). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 300mg 70518 2911 01)

Gabapentin is a prescription drug that comes in the form of a capsule containing 300 mg of the active ingredient. It is manufactured by Aurcbindo Pharma in Dayton, NJ and is available only by prescription. The capsule has an NDC number of 70518-2911-01, and it should be stored at a temperature between 20-26°C (63-77°F), with temporary excursions permitted to 15-30°C (59-86°F) as per USP. It has been repackaged by RemedyRepack Inc., Indiana, PA 15701. The package insert should be consulted for directions on how to use this medication. It is important to keep this medication out of the reach of children.*

FDA Label Image

Mm3 (Gabapentin 300mg 70518 2911 02)

Gabapentin 300 mg capsules, with a quantity of 28. Prescription only. The medication has a National Drug Code of 70518-2911-02, and was manufactured by Aurcbindo Pharma in Dayton, NJ. The medication should be stored between 20-26°C (63-77°F) with excursions permitted to 15-30°C (59-86°F) [See USP]. The packaging contains directions for use in a package insert. This particular medication was repackaged by RemedyRepack Inc. in Indiana, PA. Keep all medication out of the reach of children. The lot number and expiration date are not available.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin is a medication available in capsule form with a strength of 300 mg. The package contains 100 capsules and it is a prescription drug. The National Drug Code (NDC) for this product is 70518-2911-00. The medication is manufactured by Aurcbindo Pharma in Dayton, NJ. The lot number and expiration date are not available. The directions for use are provided in the package insert. The medication should be stored between 20-26°C (63-77°F) and can be stored at temperatures between 15-30°C (59-86°F) as allowed by USP standards. The product has been repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Formula (Gabapentin Fig1)

This appears to be a formula for calculating Lt (possibly related to kidney function) based on the age and weight of a patient, as well as their creatinine levels (which may differ for male and female patients). However, without additional context, it is difficult to determine the exact purpose or application of this formula.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

The text appears to be a chart or graph displaying mean pain scores over time, with a baseline and 7 weeks of data. The chart also shows two treatments - placebo and gabapentin at a dosage of 3600 mg/day. However, without additional context, it is unclear what type of pain is being measured or the significance of the data.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

The text provides a chart showing the mean pain score for different treatments over a period of 3-4 weeks. The treatments include a placebo, Gabapentin at a dose of 1800 mg/day, and Gabapentin at a dose of 2400 mg/day. The chart also includes a baseline measurement.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

This document appears to be a graph or chart showing the percentage of responders in controlled studies on postherpetic neuralgia, a type of nerve pain. The graph shows the proportion of patients who experienced at least a 50% reduction in their pain score. The graph compares the efficacy of different treatments, including an unspecified placebo treatment and treatments with different dosages of gabapentin (GBP). There are two studies being compared, each with its own bar graph. There are also statistical analyses shown, including p-values.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

FDA Label Image

Chemical Structure (Gabapentin Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.